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The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% ofpatients with acute myeloid leukemia (AML). Because of the poorprognosis associated with FLT3-internal tandem duplication mutat-
ed AML, allogeneic hematopoietic stem-cell transplantation (SCT) was
commonly performed in first complete remission. Remarkable progress
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Introduction
FMS-like tyrosine kinase 3 (FLT3) is a transmembrane
ligand-activated receptor tyrosine kinase that is normally
expressed by hematopoietic stem cells and early myeloid
and lymphoid progenitor cells, and is involved in the pro-
liferation, differentiation and apoptosis of hematopoietic
cells1 through various signaling pathways, including phos-
phatidylinositol 3-kinase (PI3K) and rat sarcoma (RAS) sig-
nal-transduction cascades.2-7 FLT3 is mutated in about 25-
30% of newly diagnosed cases of acute myeloid leukemia
(AML),8-10 either by internal tandem duplications (FLT3-
ITD) of the juxtamembrane domain (19-25%), and/or by
a point mutation, usually involving the tyrosine kinase
domain (TKD) at D835 or I836 in the activating loop (7-
10%).11-13 Both mutations are more frequent in cytogeneti-
cally normal AML and both constitutively activate FLT3
causing dimerization in a ligand-independent manner,
resulting in proliferation and survival of leukemia cells.14,15
FLT3-ITD mutations in newly diagnosed AML are asso-
ciated with a greater disease burden, manifesting as an ele-
vated white blood cell count and a high percentage of
blasts at the time of diagnosis as well as a tendency to
early relapse and a poor overall prognosis.8,10-12,16,17 Both
European LeukemiaNet (ELN) recommendations and
National Comprehensive Cancer Network (NCCN) guide-
lines incorporate FLT3-ITD mutations in risk-stratifying
patients based on allelic burden and nucleophosmin-1
(NPM1) co-mutation.18,19 In cytogenetically normal
patients, FLT3-ITD mutations in the presence of a con-
comitant NPM1 mutation, mainly when the FLT3-ITD
allele ratio is low (<0.5), fare better than those with wild-
type NPM1.8,10,16,17,20-22 Despite the great effort to harmonize
and cross-validate the FLT3 assays within clinical trials,23
there is still no consensus on the FLT3-ITD allele ratio
threshold and there is considerable variability between
centers in the assessment of the FLT3-ITD ratio according
to the technique used, if one is available. Furthermore, in
addition to NPM1 mutations, a significant overlap with
other mutations (WT1, IDH1, DNMT3A) as well as
NUP98/NSD1 fusions modify outcome as well as
response to therapy. Although patients with FLT3-ITD
AML respond to conventional induction chemotherapy
with remission rates similar to those seen in other sub-
types of AML, they are much more likely to relapse and to
relapse quickly.11,12,24-28 The prognostic impact of FLT3-TKD
is less clear,29-32 but it, too, is influenced substantially by
NPM1 co-mutation which confers a better prognosis.33-35
The availability of active FLT3 inhibitors that are able to
disrupt the oncogenic signaling initiated by FLT3 has
improved the overall survival (OS) of patients with FLT3-
mutated AML.36 Midostaurin, a multikinase inhibitor, was
granted Food and Drug Administration (FDA) and
European Medicines Agency (EMA) approval for the treat-
ment of patients with newly diagnosed FLT3-mutated
AML, in combination with intensive chemotherapy, and
by the EMA in addition as maintenance treatment after
conventional consolidation therapy. This approval was
based on the results of the RATIFY trial, which demon-
strated that the combination of midostaurin with standard
induction therapy resulted in significantly prolonged OS
(not censored for transplant) for AML with either FLT3-
ITD or FLT3-TKD mutations.37 The benefit was particular-
ly remarkable in patients who went on to receive allo-
geneic hematopoietic stem cell transplantation (allo-SCT)
in first complete remission (CR1). Following the results of
the ADMIRAL trial, gilteritinib, a second-generation FLT3
inhibitor, was recently approved for relapsed/refractory
FLT3-mutated AML with FLT3-ITD and FLT3-TKD muta-
tions.38 Promising data were also reported for quizartinib
and crenolanib.39,40 Finally, because of its long-time avail-
ability, sorafenib has been tested, alone or in combination,
in various settings in FLT3-ITD AML, such as first-line
therapy41,42 or for the treatment of disease relapse,43-45
including after failure of allo-SCT.45-57 However, recent
data appear to support incorporating sorafenib into the
treatment of patients with FLT3-mutated AML, possibly
with induction therapy41,58,59 as well as maintenance thera-
py after allo-SCT.43,60-65
Because of the diversity in FLT3-mutated AML, which
depends on the type of FLT3 mutation, FLT3-ITD allelic
burden, insertion site and co-occurring mutations, the
decision regarding whether to perform allo-SCT in CR1 is
becoming more challenging.66-75 With the use of more
effective therapies, especially with the incorporation of
FLT3 inhibitors, deeper responses are being achieved. The
assessment of minimal/measurable residual disease
(MRD) at the time of response has enabled prediction of
outcomes in AML, and tailoring of post-remission thera-
peutic strategies accordingly.76-78 Additionally, substantial
progress has been made in allo-SCT in recent years,
including improvement of transplant techniques, the use
of haplo-identical donors in patients lacking an HLA-
matched donor,79-81 and post-transplant preventive strate-
gies, such as prophylactic or preemptive use of FLT3
inhibitors.63,82-85 Nevertheless, current transplant strategies
has been made in frontline treatments with the incorporation of FLT3 inhibitors and the development of
highly sensitive minimal/measurable residual disease assays. Similarly, recent progress in allogeneic
hematopoietic SCT includes improvement of transplant techniques, the use of haplo-identical donors in
patients lacking an HLA matched donor, and the introduction of FLT3 inhibitors as post-transplant main-
tenance therapy. Nevertheless, current transplant strategies vary between centers and differ in terms of
transplant indications based on the internal tandem duplication allelic ratio and concomitant nucleophos-
min-1 mutation, as well as in terms of post-transplant maintenance/consolidation. This review generated
by international leukemia or transplant experts, mostly from the European Society for Blood and Marrow
Transplantation, attempts to develop a position statement on best approaches for allogeneic hematopoi-
etic SCT for AML with FLT3-internal tandem duplication including indications for and modalities of such
transplants and on the potential optimization of post-transplant maintenance with FLT inhibitors.
vary between centers and differ in terms of indications for
the transplants and treatments following them. This
review provides a consensus from European Society for
Blood and Marrow Transplantation (EBMT) experts on
best approaches to allo-SCT in AML with FLT3-ITD
including the indications for and modalities of allo-SCT
and on potential optimization of post-transplant mainte-
nance therapy with FLT3 inhibitors.
The consensus process
Two chairpersons (AB and MM) appointed a panel of 32
physicians (hereafter referred to as the Panel) selected
mostly from the EBMT) for their expertise in research and
clinical practice in AML and allo-SCT. A physician with
expertise in clinical epidemiology (ML) ensured the
methodological correctness of the process. The objective of
the Panel was to identify practical issues pertinent to all
physicians involved in the therapeutic management of
patients undergoing allo-SCT for AML with FLT3 muta-
tions and to generate best practice recommendations on
indications for and modalities of allo-SCT and on potential
optimization of post-transplant maintenance with FLT3
inhibitors. This was done through a number of questions
according to the Delphi technique.86 A search for relevant
literature in English was performed in the MEDLINE,
EMBASE and PubMed databases (up to August 2019).
Most of the studies used for these recommendations are
retrospective cohort studies or phase II trials, with only a
few prospective randomized trials. Three panelists drafted
statements that addressed the key questions identified, and
the remaining panelists scored their agreement with those
statements and provided suggestions for rephrasing them. 
The evaluation of evidence and the subsequent recom-
mendations were graded according to the system used by
Couriel.87 The strength of the recommendations (Online
Supplementary Table S1) and evidence levels (Online
Supplementary Table S2) were rated by all participants of
the consensus process.
Overview of prognosis and current indications 
for allogeneic stem-cell transplantation in 
FLT3-mutated acute myeloid leukemia
The indication for allo-SCT in FLT3-ITD AML depends
largely on FLT3 variables (allelic burden, insertion site and
co-occurring mutations), on disease status (including
MRD), and on the use of FLT3 inhibitors during induc-
tion/consolidation treatment, in addition to other
patient-, donor- and graft-related factors. Unfortunately,
there are no prospective randomized trials evaluating the
best post-remission therapeutic strategy in FLT3-mutated
AML, taking in consideration all the diverse combinations. 
Several recent reports have suggested that allele burden
might affect prognosis of FLT3-ITD AML treated with
standard induction chemotherapy.17,22,88,89 Indeed, the pres-
ence of a high allelic burden of FLT3-ITD mutations (≥0.5)
confers a poor prognosis.12,27,90,91 Several studies have
demonstrated that allo-SCT significantly improves sur-
vival outcomes in this category69, 92-95 and that the negative
impact of high allele burden might be overcome when
patients undergo allo-SCT in CR1.17 Therefore, all patients
with FLT3-ITDhigh should be considered for allo-SCT in
CR1.66,69,92-96 These patients still face higher rates of early
relapse and poor responses to further therapy and eventu-
ally poor long-term survival.92,97 The worst prognosis is
observed in patients who relapse after allo-SCT, who have
predicted 1-year OS rates below 20%.98 However, a sub-
category of patients with FLT3-ITDhigh/NPM1 mutation of
the ELN intermediate-risk group treated with FLT3
inhibitors, and who achieve MRD negativity, may be
offered the possibility of post-remission consolidation
with longitudinal MRD monitoring of NPM1.91 This
approach should be undertaken with caution, and prefer-
ably within a clinical trial, since recent data suggest the
possible extinction of the NPM1 clone after chemothera-
py while the FLT3-ITD clone persists.
Additional mutations may, however, influence the prog-
nosis of AML with FLT3-ITD. For example, the co-exis-
tence of NPM1 mutation with FLT3-ITD is associated
with improved outcomes, particularly in patients with a
low FLT3 allelic ratio (<0.5).8,10,16,20 According to the 2017
ELN recommendations, this subcategory is stratified as
favorable risk, advocating against the need for allo-SCT.91
Nonetheless, the good prognosis of a low allelic ratio is
not universally recognized, with data suggesting better
outcome for allografted patients regardless of NPM1
mutation status.99 A threshold for FLT3 allelic burden is
also controversial and differs according to studies. It was
mainly based on the median of the mutant-to-wildtype
ratio found in different retrospective studies. For example,
in one study evaluating the prognostic factors of newly
diagnosed AML, a FLT3 ratio above 0.78 was associated
with worse survival, whereas in another study the thresh-
old was 0.51.11,17 Therefore, the allelic burden has a contin-
uous effect on survival outcomes and a ratio of 0.5 is a
chosen threshold based on maximum clinical prognostic
data. With the advent of FLT3 inhibitors in the frontline
treatment of FLT3-mutated AML, the OS has improved
regardless of the allelic burden and the use of allo-SCT.
Whether NPM1-mutant FLT3-ITDlow AML warrants post-
remission allo-SCT in CR1 or not is still debatable.
Although some studies analyzing the effect of allo-SCT in
patients with NPM1-mutant FLT3-ITDlow found no
improvement in OS or relapse risk, we must take into con-
sideration the retrospective nature of the analysis and the
small number of patients with a non-statistically signifi-
cant improvement in OS and relapse risk.17,22 Interestingly,
patients with newly diagnosed AML with NPM1-mutant
FLT3-ITDlow treated with frontline midostaurin and inten-
sive chemotherapy, had a 3-year OS rate of around 75%.
In a retrospective subgroup analysis, the benefit of allo-
SCT was only seen in the adverse ELN subgroup [hazard
ratio (HR)=0.39; P=0.003], but not in the favorable
(HR=0.78; P=0.62) and intermediate risk subgroups
(HR=0.81; P=0.53).91 These findings should, however, be
interpreted with caution as the RATIFY trial was not pow-
ered to demonstrate a difference of benefit of allo-SCT
among diverse FLT3-ITD/NPM1 genotypes. For example,
the total number of patients in the favorable ELN sub-
group was 85 and these patients were divided into four
small groups according to whether they did or did not
receive midostaurin and/or allo-SCT in CR1.91
The deleterious effect of FLT3-ITD was most clinically
relevant in patients with concomitant NPM1 and
DNMT3A mutations, suggesting that AML patients with
NPM1, FLT3-ITD and DNMT3Amutations (triple-positive
AML) should be transplanted regardless of the FLT3-ITD
allelic ratio.8 A recent study conducted on 147 patients
EBMT ALWP recommendation for allo-SCT for FLT3 AML
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found that NPM1-positive AML with low allelic FLT3-
ITD still had an unfavorable outcome, with an OS rate of
only 41%, but with significant improvements in both
relapse-free survival (RFS) and OS for those allografted in
CR1.99 This challenges the notion of withholding trans-
plant for patients with supposedly favorable outcomes. In
that sense, a recent study from the MD Anderson Cancer
Center showed that allo-SCT improved leukemia-free sur-
vival (LFS) and OS independently of the FLT3-ITD allelic
ratio and NPM1 mutation status.100 This fits with recent
NCCN guidelines still offering allo-SCT for all patients
with FLT3-ITD mutations regardless of allelic ratio or
NPM1 mutation status.18
On the other hand, patients with a low allelic ITD ratio
lacking an NPM1mutation (and lacking other adverse risk
mutations) are currently considered intermediate risk,
hence in a gray prognostic area with no proper consensus
on optimal treatment strategy. There is conflict regarding
the current practice between proceeding to allo-SCT for
these patients or limiting allo-SCT only to those who do
not achieve MRD negativity by multiparametric flow
cytometry. Indeed, technical limitations prevent the use of
FLT3mutation for assessment of MRD which must there-
fore rely on multiparametric flow cytometry.101 Finally,
Versluis et al. reported that in patients with wildtype
NPM1 AML without FLT3-ITD or with a low allelic ratio
of FLT3-ITD, reduced intensity conditioning allo-SCT
resulted in better OS and RFS rates as compared with
chemotherapy or autologous SCT.89
Overall, limitations to the universal incorporation of
FLT3-ITD allelic ratio into routine clinical practice and the
treatment algorithm include the lack of a clear cut-off (0.5
in the ELN recommendations, 0.7 in the RATIFY study)
and the potential variability of the allelic ratio over time. A
global effort is needed to standardize the technique for
determining the FLT3-ITD allelic ratio, making it universal
with calibration of all laboratories, reminiscent of the glob-
al exercise the world did for BCR/ABL1. Similarly, the def-
inition of high and low allelic ratio should also be standard-
ized with a clear consensus on a cut-off level. Until these
technical challenges are addressed, the transplant indica-
tion remains controversial in patients with FLT3-ITD who
belong to the ELN favorable risk group (low allelic ratio
<0.5 with concomitant NPM1 mutation) and who achieve
MRD negativity. Many European cooperative groups fol-
low the ELN algorithm, deferring allo-SCT in patients with
NPM1-mutant FLT3-ITDlow, unless there is molecular per-
sistence of NPM1. Thus, performing MRD assessment reg-
ularly to decide on allo-SCT timing is crucial when select-
ing this approach. Conversely, the NCCN guidelines are
still advocating allo-SCT in CR1 in this setting. 
Finally, data on the prognosis of FLT3-TKD AML remain
conflicting, with some studies suggesting a negative
impact of TKD mutations on LFS and OS,11,25,30 while oth-
ers suggesting no prognostic effect, or even a benefit when
a NPM1 mutation is present.29,32,34,35
Hematopoietic stem cell transplantation and
factors predictive of outcome
As stated above, because of the poor prognosis associat-
ed with FLT3-ITD mutated AML, allo-SCT was most fre-
quently performed in patients in CR166-74,102 including fit
patients ≥60 years of age.103 In most studies, the LFS rate at
2 years ranges between 50 to 60% in that setting,66,92,97,104
although a wide variation from 20%70,105 to 70%69 has been
reported. There are knowledge gaps about the factors that
can predict outcome after allo-SCT. 
A previous EBMT study97 reported that patients with
FLT3-ITD mutated AML with concomitant mutated
NPM1 had better post-transplant outcomes compared to
those with wildtype NPM1. Similarly, other studies
reported that the presence of active disease or MRD
before allo-SCT results in poor post-transplant out-
comes.106,107 
A recent, large EBMT registry study assessed outcomes in
462 allografted FLT3-mutated AML patients with a median
follow-up of 39 months for alive patients.63 Forty percent
received allo-SCT from matched related donors, 49% from
matched unrelated donors and 11% from haploidentical
donors. Two-year cumulative incidence of relapse (CIR)
and non-relapse mortality rates were 34% and 15%,
respectively, whereas LFS, OS and graft-versus-host disease
(GvHD)-free. relapse-free survival (GRFS) rates were 51%,
59% and 38%, respectively. On multivariable analysis, the
need for more than one induction treatment negatively
affected outcome, while prescribing an allo-SCT in CR1
resulted in improved CIR, LFS and OS. Presence of an
NPM1mutation was also associated with better outcomes,
including better CIR, LFS, OS and GRFS. Post-transplant
maintenance therapy with sorafenib significantly reduced
the CIR and improved LFS, OS and GFRS. Outcomes were
not affected by the type of donor or conditioning intensity.
An important finding from this study was that in vivo T-cell
depletion with antithymocyte globulin decreased chronic
GvHD and significantly improved LFS, OS and GRFS, with-
out an apparent increase in the risk of relapse. This indi-
cates that, even in the setting of FLT3-mutated AML, in vivo
T-cell depletion does not appear to abrogate the graft-versus-
leukemia effect. Finally, the use of haplo-identical donors
was associated with improved GRFS compared to that
achieved with other types of donors. Given the high risk of
rapid relapse of patients with FLT3-mutated AML in CR1
and the poor outcome of allo-SCT in CR2 or beyond,11,12,108
these results and those of a recent EBMT study suggest that,
in the absence of a matched sibling donor, performing
haplo-identical transplants in CR1 may be considered.109
Furthermore, in another large EBMT study on more than
6,500 adult AML patients allografted in CR1, multivariate
analysis confirmed the lack of a statistically significant dif-
ference in OS following transplants from matched related
donors or 10/10 matched unrelated donors, or haplo-SCT.110
Finally, the results of a CIBMTR, EUROCORD and EBMT
collaborative analysis demonstrated that outcomes after
umbilical cord blood transplantation are similar to those
after allo-SCT from sibling donors for patients with FLT3-
ITD AML.110
Post-transplant maintenance in FLT3-mutated
acute myeloid leukemia
Even after allo-SCT, FLT3-mutated AML is associated
with a higher risk of early relapse (30%-59%) compared
to FLT3-wildtype AML.82,92 Indeed, in a CIBMTR analysis
of 511 patients (158 with FLT3 mutations), there was an
increase in relapse rates in FLT3-mutated AML (38% vs.
28%; P=0.04; relative risk 1.60; 95% CI: 1.15-2.22).74
Satisfactory treatment of patients with FLT3-mutated
AML who relapse or progress after allo-SCT, is an unmet
need. Chemotherapy or FLT3 inhibitors alone or com-
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bined with donor lymphocyte infusions are rarely effec-
tive in the long term,45-50 even though a small proportion
of patients who relapse after allo-SCT can achieve long-
lasting responses with sorafenib.52,54,55,57 A second allo-SCT
can be offered to only a small percentage of patients and
is associated with a rather high non-relapse mortality
rate.111 Several studies have, therefore, investigated the
use of post-transplant maintenance with FLT3 inhibitors
as a strategy aimed to reduce relapse after allo-SCT.112
Midostaurin was not offered as maintenance therapy to
recipients of allo-SCT in the RATIFY study,113 but the
RADIUS phase II randomized trial compared post-trans-
plant midostaurin maintenance with standard care in 60
adult patients.114 Estimated relapse rates at 18 months
were 24% in the standard care group and 11% in the
midostaurin group (P=0.27).114 In another prospective
phase II study, maintenance midostaurin was also offered
to FLT3-mutated AML patients undergoing allo-SCT in
CR1. In a landmark analysis in patients who were event
free at day 100 after transplant (n=116), those who start-
ed maintenance therapy within 100 days after their trans-
plant (n=72) had a significantly better OS than those who
did not.115 The main cause of early discontinuation of
maintenance midostaurin after allo-SCT (23%) was poor
tolerability, mainly as a result of gastrointestinal toxici-
ty.114
Sorafenib has been studied as maintenance therapy fol-
lowing allo-SCT, demonstrating benefit with regards to
survival and improved outcomes in a phase I study, a pilot
study, a single-center study, a multicenter study, a registry
study and a randomized study.60-65,116 A phase I trial
(NCT01398501) was conducted in which 22 FLT3-ITD
AML patients received twelve 28-day cycles of sorafenib
45-120 days after allo-SCT.61 The maximum tolerated
dose was established at 400 mg twice daily.  The 1-year
progression-free survival (PFS) rate was 85% with a cor-
responding 1-year OS of 95%. In a pilot study, six
patients with FLT3-ITD AML received sorafenib (n=5
maintenance, n=1 salvage) after allo-SCT with similarly
encouraging results.116 Five of these patients developed
cutaneous corticosteroid-sensitive GvHD within a few
days after sorafenib initiation, suggesting a possible
immunomodulatory effect, and remarkably all patients
had sustained molecular remissions.
In a single-institution, observational study on FLT3-ITD
AML patients transplanted in CR1, 26 patients who
received sorafenib as maintenance treatment after allo-
SCT were compared to 55 historical controls who did
not.62 The sorafenib cohort had a better 2-year OS rate
(81% vs. 62%), improved PFS (82% vs. 53%), and lower
relapse incidence (8% vs. 38%).  
In a multicenter study, 27 FLT3-mutated AML patients
(aged 15-57 years) received maintenance therapy with
sorafenib as a single agent after allo-SCT.60 At a median
follow-up of 18 months, 25 patients were in complete
remission with full donor chimerism, with 1-year PFS and
OS rates reaching 92%. Updated results after a median
follow-up of 40 months further demonstrated favorable
long-term outcomes in patients receiving sorafenib main-
tenance therapy, with 2-year PFS and OS rates reaching
73% and 80%, respectively, with an acceptable toxicity
profile.65
A recent large EBMT registry study assessed outcomes
in 462 allografted FLT3-mutated AML patients over a
median follow-up of 39 months for surviving patients.63
Twenty-eight patients received post-transplant sorafenib
maintenance treatment, initiated at a median of 55 days
after transplantation (range, 1-173) at a median dose of
800 mg/day (range, 200-800 mg/day). Thirteen patients in
the sorafenib group had chronic GvHD at a median time
of 76 days after the initiation of sorafenib (range, 9-194
days). Chronic GvHD was limited in seven patients and
extensive in six. On multivariate analysis, post-transplant
maintenance with sorafenib significantly reduced the
relapse incidence (HR=0.39; P=0.05), and improved LFS
(HR=0.35; P=0.01), OS (HR=0.36; P=0.03) and GFRS
(HR=0.44; P=0.02). Matched-pair analysis was also per-
formed on 52 patients (26 in the sorafenib group and 26
controls) who engrafted and survived after allo-SCT with
no relapse or grade II-IV acute GvHD until sorafenib ini-
tiation. The 2-year LFS and OS rates were 79% and 83%,
respectively, in the sorafenib group (P=0.02) versus 54%
and 62%, respectively, in the controls (P=0.007). 
More recently, preliminary conclusions of a double-
blind, prospective trial (SORMAIN) that randomized
patients to either maintenance treatment with sorafenib
or placebo introduced during the first 60-100 days after
allo-SCT provided further support for the use of this drug
in this high-risk setting.64 Eighty transplanted FLT3-ITD
adult AML patients were randomized 1:1 to receive either
sorafenib (up to 400 mg twice daily) or placebo for up to
24 months. After a median follow-up of 42 months, the
median RFS was 31 months in the placebo group whereas
it was ‘not reached’ in the sorafenib group (corresponding
to a 2-year RFS of 53% vs. 85%: HR 0.39; P=0.01).
Sorafenib was well-tolerated with toxicities that were
generally manageable, mostly by dose reduction. These
findings build on previously reported data and confirm
that sorafenib maintenance therapy after allo-SCT in
FLT3-ITD AML patients is both safe and efficient in sig-
nificantly reducing CIR and improving survival.
In addition to sorafenib’s direct anti-leukemic effect, a
possible synergism between the drug and alloreactive
donor T cells in facilitating long-term disease control has
been suggested,117 and has also been proposed in murine
models in which sorafenib apparently exacerbated
GvHD.118 A recent study demonstrated that sorafenib pro-
motes graft-versus-leukemia activity in mice and humans
through interleukin-15 production in FLT3-ITD leukemia
cells.119
Gilteritinib is also currently being prospectively
assessed for maintenance use in FLT3-ITD AML after allo-
SCT in a phase III, randomized, double-blind, placebo-
controlled multicenter trial (NCT02997202).120 This study
aims to enroll 346 adult patients with AML in CR1, ran-
domized 1:1, to receive either gilteritinib 120 mg or place-
bo for 2 years. In addition, a large phase III randomized
study (NCT04027309) by a consortium of several cooper-
ative study groups, including HOVON, AMLSG, SAKK,
ALFA, CETLAM, PETHEMA, FILO and ALLG, is antici-
pated to start enrolling by the end of 2019: patients will
be randomized to midostaurin or gilteritinib added to
standard induction and consolidation treatment. Patients
who achieve complete remission will continue mainte-
nance with either midostaurin or gilteritinib. 
Finally, the recent approval of midostaurin for frontline
treatment of FLT3-mutated AML in the USA and Europe
may challenge the role of post-transplant maintenance
therapies, including sorafenib. Accordingly, new data
should be generated in this setting.121,122 Most FLT3-mutat-
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ed AML patients, however, are not currently receiving
midostaurin, at least outside the USA and some other
countries; therefore, for the foreseeable future, patients
may still benefit from sorafenib maintenance treatment
after allo-SCT.
Summary of position statement (Table 1)
1- Indications for allogeneic stem-cell transplantation
in FLT3-internal tandem duplication acute myeloid
leukemia
• The indication for allo-SCT is controversial in patients
with FLT3-ITD who belong to the ELN favorable risk
group (low allelic ratio <0.5 with concomitant NPM1
mutation) and who achieve MRD negativity. Allo-SCT
may be delayed until first relapse as recommended by the
ELN or performed in CR1 as allowed by NCCN guide-
lines. Grade level C-II
• In general, all other patients with FLT3-ITD AML
should be considered for allo-SCT in CR1 if feasible.
Grade level B-II
2- Modalities of hematopoietic stem cell 
transplantation
• Donors should be selected according to EBMT general
guidelines83 including the potential use of cord blood grafts
whenever indicated. Grade level B-II
• In vivo T-cell depletion decreases the risk of chronic
GvHD, without apparently increasing the risk of relapse,
in FLT3-ITD AML and is therefore an option in this set-
ting. Grade level B-II
• The choice of conditioning has no direct link with
FLT3-ITD mutation and should be adapted to other indi-
vidual risk factors such as age, disease status at transplant,
and donor type. Grade level B-II
3- Post-transplant maintenance for FLT3-internal tan-
dem duplication acute myeloid leukemia
• Post-transplant maintenance therapy with a FLT3
inhibitor for patients who have undergone allo-SCT for
FLT3-ITD AML is recommended (except for patients with
active acute GvHD). In the absence of an appropriate clin-
ical trial, sorafenib could be considered as the preferred
option, but other FLT3 inhibitors are attractive and war-
A. Bazarbachi et al.
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Table 1. Summary of the European Society for Blood and Marrow Transplantation position statement on allogeneic hematopoietic stem-cell trans-
plantation in FLT3-internal tandem duplication acute myeloid leukemia.
Indication for allo-SCT         Transplant indication is controversial in patients with FLT3-ITD who belong to the ELN favorable risk group (low allelic 
in FLT3 mutated AML             ratio <0.5 with concomitant NPM1mutation) and who achieve MRD negativity. Allo-SCT may be delayed until first relapse 
                                                              as recommended by the ELN or performed in CR1 as allowed by NCCN guidelines.
                                                              
                                                              In general, all other patients with FLT3-ITD should be considered for allo-SCT in CR1 if feasible.
Modalities of allo-SCT           Donor selection according to EBMT general guidelines.
                                                              In vivo T-cell depletion decreases the risk of chronic GVHD without an apparent increase in the risk of relapse in FLT3
                                                              mutated AML and is therefore an option in this setting.
                                                              The choice of conditioning has no direct link with FLT3mutation and should be adapted to other individual risk factors 
                                                              such as age, disease status at transplant, and donor type.
Post-transplant                          Post-transplant systemic maintenance therapy with a FLT3 inhibitor for patients who underwent allo-SCT for FLT3-ITD 
maintenance                                AML is recommended (except for patients with active acute GvHD). 
                                                              In the absence of an appropriate clinical trial, sorafenib could be considered as the preferred option, but the role of 
                                                              other FLT3 inhibitors warrants investigation.
                                                              Maintenance treatment should be initiated as soon as possible after disease evaluation, including MRD assessment, 
                                                              especially in  patients with MRD-positive AML before or after allo-SCT, provided there is adequate hematologic 
                                                              reconstitution.
                                                              The recommended post-transplant maintenance is sorafenib at a dose of 400 mg/day in two divided doses. Patients with
                                                              MRD-positive disease may receive 800 mg/day in two divided doses, to be adapted according to tolerance. Sorafenib 
                                                              should be transiently discontinued in the case of GvHD requiring systemic treatment with corticosteroids, but may be 
                                                              cautiously resumed once remission of GvHD is documented.
                                                              Ongoing studies will determine whether midostaurin, gilteritinib or other FLT3 inhibitors will become additional 
                                                              alternatives in this setting.
                                                              Maintenance therapy duration is not firmly established, but a minimum of 2 years is recommended, depending 
                                                              on tolerance.
Allo-SCT: allogeneic hematopoietic stem cell transplantation; FLT3: FMS-like tyrosine kinase 3; AML: acute myeloid leukemia; FLT3-ITD: FLT3-internal tandem duplication; ELN:
European LeukemiaNet; NPM1: Nucleophosmin 1; MRD: minimal residual disease; CR1: first complete remission; NCCN: National Comprehensive Cancer Network; EBMT:
European Society for Blood and Marrow Transplantation; GvHD: graft-versus-host disease..
rant further investigation in larger prospective studies.
Grade level B-II
• Maintenance therapy should be initiated as soon as
possible after disease evaluation, including MRD assess-
ment (whenever feasible), especially in patients with
MRD-positive AML before or after allo-SCT, provided
there is adequate hematologic reconstitution. Grade level
B-II
• Sorafenib should be transiently discontinued in the
case of GvHD requiring systemic treatment with corticos-
teroids, but may be cautiously resumed once remission of
GvHD is documented. Grade level B-III
• If choosing sorafenib, the recommended post-trans-
plant maintenance dose is 400 mg/day in two divided
doses. Patients with MRD-positive disease may receive
800 mg/day in two divided doses, to be adapted according
to tolerance. Grade level B-III
• One potential challenge is the lack of approval of
sorafenib for AML and its off-label use may not be reim-
bursed in many/most countries. Ongoing studies will
determine the role and modalities of use of midostaurin,
gilteritinib or other FLT3 inhibitors in this setting.
• The duration of maintenance therapy is not firmly
established, but a minimum of 2 years is recommended,
depending on tolerance. Grade level B-III
• Monitoring is recommended for potential drug-drug
interactions and long-term side effects.
Aspects to be resolved
•  Standardization of FLT3-ITD allelic ratio in terms of
technique and cut-off level
• Indication for allo-SCT in patients with FLT3-ITD
AML who belong to the ELN intermediate risk group
(high allelic ratio ≥0.5 with concomitant NPM1 mutation)
and who achieve MRD negativity.
• Time of withdrawal of immunosuppression 
• Pre-emptive versus prophylactic donor lymphocyte
infusion
• Post-transplant maintenance with FLT3 inhibitors out-
side FLT3-ITD AML (immunomodulatory and off-target
effects)
• Impact of post-transplant maintenance therapy on
immune reconstitution and environment
• Combination of post-transplant FLT3 inhibitors with
other drugs such as hypomethylating agents
• Monitoring of patients receiving post-transplant FLT3
inhibitors for potential extramedullary relapse or aggres-
sive clone selection.
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